Ausgabe 4/2018
Inhalt (25 Artikel)
Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells
Jade K. Pollock, Lisa M. Greene, Seema M. Nathwani, Paula Kinsella, Niamh M. O’Boyle, Mary J. Meegan, Daniela M. Zisterer
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
S. Betty Yan, Suzane L. Um, Victoria L. Peek, Jennifer R. Stephens, Wei Zeng, Bruce W. Konicek, Ling Liu, Jason R. Manro, Volker Wacheck, Richard A. Walgren
Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis
Hak-Min Lee, Eunmyong Lee, So-Young Yeo, Sang Shin, Hyun-Kyu Park, Do-Hyun Nam, Seok-Hyung Kim
Development of a dietary formulation of the SHetA2 chemoprevention drug for mice
Doris M. Benbrook, Naveena B. Janakiram, Vishal Chandra, Gopal Pathuri, Venkateshwar Madka, Nicole C. Stratton, Chioniso P. Masamha, Cassadie N. Farnsworth, Lucila Garcia-Contreras, Manolya Kukut Hatipoglu, Stan Lighfoot, Chinthalapally V. Rao
Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway
Jianan Zhou, Canjing Zhang, Xianxian Sui, Shengxuan Cao, Feng Tang, Shuhui Sun, Songmei Wang, Bobin Chen
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells
Alexandra Canonici, Zulfiqar Qadir, Neil T. Conlon, Denis M. Collins, Neil A. O’Brien, Naomi Walsh, Alex J. Eustace, Norma O’Donovan, John Crown
Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation
Hsiu-Yu Liu, Andrea Z. Tuckett, Myles Fennell, Ralph Garippa, Johannes L. Zakrzewski
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Rivka R. Colen, Takeo Fujii, Mehmet Asim Bilen, Aikaterini Kotrotsou, Srishti Abrol, Kenneth R. Hess, Joud Hajjar, Maria E. Suarez-Almazor, Anas Alshawa, David S. Hong, Dunia Giniebra-Camejo, Bettzy Stephen, Vivek Subbiah, Ajay Sheshadri, Tito Mendoza, Siqing Fu, Padmanee Sharma, Funda Meric-Bernstam, Aung Naing
Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations
Motohiro Tamiya, Akihiro Tamiya, Takayuki Shiroyama, Sawa Takeoka, Yujiro Naito, Naoki Omachi, Yohei Kimura, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi, Tomonori Hirashima
Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy – results of an exploratory phase I study
H. Pappot, H. von der Maase, A. Ullén, M. Agerbæk
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors
Rastislav Bahleda, Marie-Cécile Le Deley, Apexa Bernard, Shalini Chaturvedi, Michael Hanley, Audrey Poterie, Anas Gazzah, Andreea Varga, Mehdi Touat, Eric Deutsch, Christophe Massard, Helgi Van De Velde, Antoine Hollebecque, Magali Sallansonnet-Froment, Damien Ricard, Hervé Taillia, Eric Angevin, Vincent Ribrag, Jean-Charles Soria
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer
Jonathan W. Goldman, Lee S. Rosen, Anthony W. Tolcher, Kyriakos Papadopoulos, Muralidhar Beeram, Peipei Shi, Celine Pitou, Robert Bell, Palaniappan Kulanthaivel, Xuekui Zhang, Aaron Fink, Edward M. Chan, Ashwin Shahir, Daphne Farrington, Amita Patnaik
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Takeo Fujii, Rivka R. Colen, Mehmet Asim Bilen, Kenneth R. Hess, Joud Hajjar, Maria E. Suarez-Almazor, Anas Alshawa, David S. Hong, Apostolia Tsimberidou, Filip Janku, Jing Gong, Bettzy Stephen, Vivek Subbiah, Sarina A. Piha-Paul, Siqing Fu, Padmanee Sharma, Tito Mendoza, Anisha Patel, Selvi Thirumurthi, Ajay Sheshadri, Funda Meric-Bernstam, Aung Naing
A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
Hideki Ueno, Shunsuke Kondo, Shusuke Yoshikawa, Koichi Inoue, Valérie Andre, Masaomi Tajimi, Haruyasu Murakami
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition
Margaret T. Kasner, Rosemarie Mick, Grace R. Jeschke, Matthew Carabasi, Joanne Filicko-O’Hara, Neal Flomenberg, Noelle V. Frey, Elizabeth O. Hexner, Selina M. Luger, Alison W. Loren, James K. Mangan, John L. Wagner, Mark Weiss, Martin Carroll, Alexander E. Perl
A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer
Akihiro Tamiya, Masahiro Morimoto, Shoichi Fukuda, Yoko Naoki, Tatsuya Ibe, Kyoichi Okishio, Hideto Goto, Akihiro Yoshii, Toshiyuki Kita, Naoyuki Nogami, Yuka Fujita, Shinji Atagi
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Arthur Lui, Karen Mulder, Christine Brezden-Masley, Michael Vickers, Jose Monzon, Hagen Kennecke, Rakesh Goel, Larissa Vos, Sunita Ghosh, Horia Marginean, Anthony Fields, Jean Maroun, Jennifer Spratlin
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
Herbert Hurwitz, Eric Van Cutsem, Johanna Bendell, Manuel Hidalgo, Chung-Pin Li, Marcelo Garrido Salvo, Teresa Macarulla, Vaibhav Sahai, Ashwin Sama, Edward Greeno, Kenneth H. Yu, Chris Verslype, Fitzroy Dawkins, Chris Walker, Jason Clark, Eileen M. O’Reilly
Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer
Motohiro Tamiya, Hidekazu Suzuki, Takayuki Shiroyama, Ayako Tanaka, Naoko Morishita, Norio Okamoto, Kenichi Sakai, Hironori Shigeoka, Kunimitsu Kawahara, Tomonori Hirashima
Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan
Hiroki Nakayama, Katsura Tsukamoto
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients
Teresa Di Desidero, Paola Orlandi, Anna Fioravanti, Chiara Cremolini, Fotios Loupakis, Federica Marmorino, Carlotta Antoniotti, Gianluca Masi, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Alfredo Falcone, Guido Bocci
Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation
Midori Tanaka, Hidenobu Ishii, Hayato Moribuchi, Yoshiko Naito, Norikazu Matsuo, Masayuki Nakamura, Takaaki Tokito, Koichi Azuma, Kazuhiko Yamada, Tomoaki Hoshino
Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model
Hossam Draz, Alexander A. Goldberg, Emma S. Tomlinson Guns, Ladan Fazli, Stephen Safe, J. Thomas Sanderson
Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer
Yoshihisa Nakatani, Hisato Kawakami, Masashi Ichikawa, Sachiyo Yamamoto, Yasuo Otsuka, Akiko Mashiko, Yasutoshi Takashima, Akihiko Ito, Kazuhiko Nakagawa, Shuji Arima
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
Jihoon Kang, Inhwan Hwang, Changhoon Yoo, Kyu-pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Seung-Mo Hong, Sang Hyun Shin, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Song Cheol Kim, Baek-Yeol Ryoo